Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2463人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866670, encodeId=a43a18666e066, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌, objectType=article, longId=729208, objectId=e8d9e29208b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d9e29208b5, replyNumber=0, likeNumber=74, createdTime=2022-06-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d9e29208b5, moduleTitle=Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d9e29208b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866699, encodeId=2819186669940, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Bone Oncol：接受激素剥夺治疗的癌症患者脊柱骨折的预测：骨折风险评估工具(FRAX)和骨密度在现实生活临床实践中的可靠性, objectType=article, longId=737881, objectId=c156e37881ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c156e37881ae, replyNumber=0, likeNumber=0, createdTime=2023-01-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c156e37881ae, moduleTitle=J Bone Oncol：接受激素剥夺治疗的癌症患者脊柱骨折的预测：骨折风险评估工具(FRAX)和骨密度在现实生活临床实践中的可靠性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c156e37881ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866557, encodeId=79f7186655e35, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=108, createdTime=2022-10-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866408, encodeId=b990186640803, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, objectType=article, longId=291839, objectId=14f2291839cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f2291839cd, replyNumber=0, likeNumber=69, createdTime=2022-11-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f2291839cd, moduleTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f2291839cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866388, encodeId=fc6a186638863, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, objectType=article, longId=221344, objectId=e1b922134447, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1b922134447, replyNumber=0, likeNumber=64, createdTime=2022-10-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1b922134447, moduleTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1b922134447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866367, encodeId=5075186636e39, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况, objectType=article, longId=220855, objectId=b2bf220855c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2bf220855c8, replyNumber=0, likeNumber=68, createdTime=2022-04-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2bf220855c8, moduleTitle=Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2bf220855c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866580, encodeId=d58a186658085, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效, objectType=article, longId=723399, objectId=0052e23399a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0052e23399a4, replyNumber=0, likeNumber=113, createdTime=2022-09-27, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0052e23399a4, moduleTitle=Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0052e23399a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866558, encodeId=62251866558da, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, objectType=article, longId=301244, objectId=cf6f3012449f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf6f3012449f, replyNumber=0, likeNumber=62, createdTime=2022-09-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf6f3012449f, moduleTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf6f3012449f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866458, encodeId=e9461866458ee, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=61, createdTime=2022-09-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866390, encodeId=1b981866390de, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, objectType=article, longId=221380, objectId=bb87221380d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb87221380d6, replyNumber=0, likeNumber=89, createdTime=2022-09-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb87221380d6, moduleTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb87221380d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866450, encodeId=895c1866450ca, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, objectType=article, longId=293562, objectId=0e1f293562ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1f293562ed, replyNumber=0, likeNumber=94, createdTime=2022-09-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1f293562ed, moduleTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e1f293562ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866429, encodeId=2d02186642977, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, objectType=article, longId=292558, objectId=2c632925589c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c632925589c, replyNumber=0, likeNumber=60, createdTime=2022-07-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c632925589c, moduleTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c632925589c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866591, encodeId=922f1866591ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后, objectType=article, longId=724610, objectId=793de2461036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=793de2461036, replyNumber=0, likeNumber=65, createdTime=2022-08-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=793de2461036, moduleTitle=Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=793de2461036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866682, encodeId=f19c1866682d2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率, objectType=article, longId=735465, objectId=7ce2e3546529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ce2e3546529, replyNumber=0, likeNumber=89, createdTime=2023-06-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ce2e3546529, moduleTitle=Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ce2e3546529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866510, encodeId=9cb118665101d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, objectType=article, longId=295703, objectId=ea9c295e0337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9c295e0337, replyNumber=0, likeNumber=64, createdTime=2022-09-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9c295e0337, moduleTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea9c295e0337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866468, encodeId=c2b2186646839, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Acta Oncol：在临床试验之外接受治疗的慢性期老年慢性粒细胞白血病患者中一线达沙替尼的长期随访：一项现实生活中的队列观察研究, objectType=article, longId=294667, objectId=984729466e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=984729466e40, replyNumber=0, likeNumber=59, createdTime=2022-06-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=984729466e40, moduleTitle=Acta Oncol：在临床试验之外接受治疗的慢性期老年慢性粒细胞白血病患者中一线达沙替尼的长期随访：一项现实生活中的队列观察研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=984729466e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866667, encodeId=ac4b186666eaf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效, objectType=article, longId=732675, objectId=84ece326750e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ece326750e, replyNumber=0, likeNumber=114, createdTime=2023-06-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ece326750e, moduleTitle=Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ece326750e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866431, encodeId=ab181866431c9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：3期| 图像引导的调化放疗 vs 3D适形放疗用于宫颈癌术后患者的晚期毒副作用, objectType=article, longId=292999, objectId=f768292999f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f768292999f9, replyNumber=0, likeNumber=27, createdTime=2022-11-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f768292999f9, moduleTitle=J Clin Oncol：3期| 图像引导的调化放疗 vs 3D适形放疗用于宫颈癌术后患者的晚期毒副作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f768292999f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866439, encodeId=04e21866439bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, objectType=article, longId=293043, objectId=5aea293043a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aea293043a4, replyNumber=0, likeNumber=54, createdTime=2022-09-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aea293043a4, moduleTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aea293043a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866538, encodeId=ffc6186653848, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！, objectType=article, longId=300486, objectId=097730048604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=097730048604, replyNumber=0, likeNumber=83, createdTime=2022-10-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=097730048604, moduleTitle=J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=097730048604)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌

2022-06-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Bone Oncol：接受激素剥夺治疗的癌症患者脊柱骨折的预测：骨折风险评估工具(FRAX)和骨密度在现实生活临床实践中的可靠性

2023-01-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2022-10-14

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索

2022-11-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期

2022-10-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况

2022-04-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效

2022-09-27

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效

2022-09-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-09-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性

2022-09-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著

2022-09-17

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著

2022-07-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后

2022-08-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率

2023-06-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效

2022-09-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Acta Oncol：在临床试验之外接受治疗的慢性期老年慢性粒细胞白血病患者中一线达沙替尼的长期随访：一项现实生活中的队列观察研究

2022-06-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效

2023-06-14

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：3期| 图像引导的调化放疗 vs 3D适形放疗用于宫颈癌术后患者的晚期毒副作用

2022-11-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后

2022-09-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！

2022-10-25

科室
- - 订阅+
  - 更多科室
工具
服务